List of Excipients in API ibrexafungerp
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing ibrexafungerp
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| SCYNEXIS INC | BREXAFEMME | ibrexafungerp | 75788-115 | BUTYLATED HYDROXYANISOLE | 2035-01-19 |
| SCYNEXIS INC | BREXAFEMME | ibrexafungerp | 75788-115 | CELLULOSE, MICROCRYSTALLINE | 2035-01-19 |
| SCYNEXIS INC | BREXAFEMME | ibrexafungerp | 75788-115 | CROSPOVIDONE | 2035-01-19 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for ibrexafungerp
Excipient focus: BUTYLATED HYDROXYANISOLE
ibrexafungerp drug variants containing BUTYLATED HYDROXYANISOLE
| Company | Ingredient | NDC |
|---|---|---|
| SCYNEXIS INC | ibrexafungerp | 75788-115 |
| >Company | >Ingredient | >NDC |
ibrexafungerp drug variants not containing BUTYLATED HYDROXYANISOLE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CELLULOSE, MICROCRYSTALLINE
ibrexafungerp drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| SCYNEXIS INC | ibrexafungerp | 75788-115 |
| >Company | >Ingredient | >NDC |
ibrexafungerp drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CROSPOVIDONE
ibrexafungerp drug variants containing CROSPOVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| SCYNEXIS INC | ibrexafungerp | 75788-115 |
| >Company | >Ingredient | >NDC |
ibrexafungerp drug variants not containing CROSPOVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FD&C BLUE NO. 2
ibrexafungerp drug variants containing FD&C BLUE NO. 2
| Company | Ingredient | NDC |
|---|---|---|
| SCYNEXIS INC | ibrexafungerp | 75788-115 |
| >Company | >Ingredient | >NDC |
ibrexafungerp drug variants not containing FD&C BLUE NO. 2
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FD&C RED NO. 40
ibrexafungerp drug variants containing FD&C RED NO. 40
| Company | Ingredient | NDC |
|---|---|---|
| SCYNEXIS INC | ibrexafungerp | 75788-115 |
| >Company | >Ingredient | >NDC |
ibrexafungerp drug variants not containing FD&C RED NO. 40
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYDROXYPROPYL CELLULOSE
ibrexafungerp drug variants containing HYDROXYPROPYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| SCYNEXIS INC | ibrexafungerp | 75788-115 |
| >Company | >Ingredient | >NDC |
ibrexafungerp drug variants not containing HYDROXYPROPYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
ibrexafungerp drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| SCYNEXIS INC | ibrexafungerp | 75788-115 |
| >Company | >Ingredient | >NDC |
ibrexafungerp drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MANNITOL
ibrexafungerp drug variants containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| SCYNEXIS INC | ibrexafungerp | 75788-115 |
| >Company | >Ingredient | >NDC |
ibrexafungerp drug variants not containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SILICON DIOXIDE
ibrexafungerp drug variants containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| SCYNEXIS INC | ibrexafungerp | 75788-115 |
| >Company | >Ingredient | >NDC |
ibrexafungerp drug variants not containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TALC
ibrexafungerp drug variants containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| SCYNEXIS INC | ibrexafungerp | 75788-115 |
| >Company | >Ingredient | >NDC |
ibrexafungerp drug variants not containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
ibrexafungerp drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| SCYNEXIS INC | ibrexafungerp | 75788-115 |
| >Company | >Ingredient | >NDC |
ibrexafungerp drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
